Day One Biopharmaceuticals is developing therapies for patients of all ages with life-threatening diseases. The most common childhood brain cancer is pediatric low-grade glioma (pLGG), and it currently lacks effective cures. Through partnering with leading clinical oncologists, families and scientists, Day One is identifying, acquiring and developing cancer treatments. Day One’s lead product, DAY101 (tovorafenib), is in Phase 1/2 clinical trials for treatment against pLGG. DAY101 is an orally-taken, brain-penetrant pan-RAF inhibitor. Day One’s pipeline also includes pimasertib, a small molecule inhibitor of MEK-1/-2.

<p>Day One Biopharmaceuticals is developing therapies for patients of all ages with life-threatening diseases. The most common childhood brain cancer is pediatric low-grade glioma (pLGG), and it currently lacks effective cures. Through partnering with leading clinical oncologists, families and scientists, Day One is identifying, acquiring and developing cancer treatments. Day One’s lead product, DAY101 (tovorafenib), is in Phase 1/2 clinical trials for treatment against pLGG. DAY101 is an orally-taken, brain-penetrant pan-RAF inhibitor. Day One’s pipeline also includes pimasertib, a small molecule inhibitor of MEK-1/-2.</p>


Day One Biopharmaceuticals

 Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M 

Day One Reports First Quarter 2024 Financial Results and Corporate Progress - GlobeNewswire

 Join Our Legal Community job with Day One Biopharmaceuticals | 2889402 

Nature Medicine

 Day One Biopharmaceuticals 10% owner increases holding with ~$15M stock purchase 

We're proud to sponsor the Children's Brain Tumor Foundation's Fifth Annual Holiday Webathon this Sunday, 12/1. We hope you’ll join CBTF from 6:00pm - 9:00pm ET for an evening dedicated to spreading holiday cheer with families facing pediatric brain tumors.

Register here: https://cbtf.org/holiday/


                                            RESOURCES                                        

Day One Announces Oversubscribed $175.0 Million Private Placement - StockTitan

 Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair (NASDAQ:DAWN) 

Day One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric Glioma - Insider Monkey

 What 7 Analyst Ratings Have To Say About Day One Biopharmaceutical 

Insider Sale at Day One Biopharmaceuticals Inc (DAWN) - Yahoo Finance

What does it take to drive meaningful progress in pediatric drug development? According to Christa Kerkorian, VP of Patient Advocacy at Day One, the answer lies in listening to the community and fostering multistakeholder collaboration.

In this interview, hosted by Patients As Partners in Clinical Research Community News, Christa shares how insights from the pediatric cancer community inform Day One's advocacy approach and highlights key principles of engagement that guide these efforts.

Read the full interview here: https://lnkd.in/gW2R_6e9 

Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk - Nasdaq

 Day One Biopharmaceuticals reports Q3 EPS 38c, consensus (41c) 

“The Day One Talk”

Day One Biopharmaceuticals: Still Uncertainty After FDA Approval (NASDAQ:DAWN) - Seeking Alpha

Day One Biopharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference - StockTitan

 Day One Biopharmaceuticals inks research collaboration with Swedish biotech 

Ipsen builds again, licensing Day One glioma drug - pharmaphorum

CBTN Partners with Day One to Drive New Therapies for Pediatric Brain Tumors - PR Newswire


                                            Our advocacy team                                        

Childhood cancer-focused Day One snags Gilead alum ...

 Senior Medical Director, Pharmacovigilance and Patient Safety job with Day One Biopharmaceuticals | 2880375 

Day One spends day 2 hitting up public markets for $150M ...

 Day One Biopharmaceuticals Executives Sell Shares Worth Over $2.4 Million 

 Day One Biopharmaceuticals files automatic mixed securities shelf 

Expanded access

Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors - GlobeNewswire

Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug - Endpoints News

Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey


                                            OVERVIEW                                        


                                        Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial                                    

We’re looking forward to attending the J.P. Morgan Healthcare Conference. Dr. Jeremy Bender, CEO, will present on Monday, January 13, at 3:45 PM PT. 
A live audio webcast of the presentation will be available here: https://bit.ly/3UMCys7

Learn more: https://bit.ly/3ZJjr3Y

Day one Biopharmaceuticals head of R&D sells $399,339 in stock - Investing.com

www.ojemda.com

 Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates 

Day One’s Ojemda Gets FDA Accelerated Approval for Pediatric Brain Tumor - BioSpace


                                            FIREFLY-1 Clinical Trial                                        

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Consensus Target Price from Analysts - MarketBeat

Today, Day One announced that Co-Founder and Head of R&D, Dr. Samuel Blackman, MD, PhD, will be retiring from the company at the end of 2024. Read more here: https://bit.ly/3V0tccH

Samuel Blackman we thank you for your passion, commitment, and visionary leadership to not only build and bring Day One to what it is today, but to help transform the treatment landscape for children and families impacted by cancer.

 Day One Biopharmaceuticals reports Q4 results (NASDAQ:DAWN) 

Day One Biopharmaceuticals Announces Leadership Transition - TipRanks

dayoneclinicaltrials.com

Investigator-sponsored research

Visit everydaysupport.com


                                            COMMUNITY NEWS                                        

 Day One’s Ojemda Gets FDA Accelerated Approval for Pediatric Brain Tumor 

Partnering

We are excited to share our recently published manuscript in 𝘕𝘦𝘶𝘳𝘰-𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺, which details radiographic and visual response to tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial. These findings from a post-hoc analysis contribute to our understanding of treatment outcomes in this challenging condition.

Read More: https://lnkd.in/g7tw3s-Q

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 - StockTitan


              CBTN Partners with Day One to Drive New Therapies for Pediatric Brain Tumors
            

This Thanksgiving, we’re grateful for everyone who brings our mission to life. To the courageous patients and families, dedicated healthcare providers, our valued partners, and our incredible employees – thank you for inspiring hope for people of all ages facing cancer. 
 
Happy Thanksgiving to our entire community – today and every day, we are thankful for you.


 Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated 

Day One debuts with $60M to change cancer care ...

www.everydaysupport.com

Day One Biopharmaceuticals to Present at Piper Sandler Healthcare Conference - StockTitan

Day One takes on Novartis with FDA nod for Ojemda in broader common childhood brain tumor use - FiercePharma

Day One Announces Sale of Priority Review Voucher for $108 Million - GlobeNewswire

 Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects 

 Oral liquid suspension of pan-raf kinase inhibitor 

 Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress 

High Growth Tech Stocks to Watch in December 2024 - Simply Wall St

 Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development 

Leadership

 Day One Biopharmaceuticals sells FDA voucher for $108 million By Investing.com 

 Day One Reports First Quarter 2024 Financial Results and Corporate Progress 

Day One Biopharmaceuticals: Sales Figures In The Crosshairs... And What Else? - Seeking Alpha

 Peninsula biopharma wins 1st FDA approval for drug targeting type of brain cancer in kids - San Francisco Business ... 

 Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval 

 Day One pressures Novartis with FDA nod for novel RAF inhibitor 

Ipsen and Day One in ex-US tovorafenib deal for most common childhood brain tumor - The Pharma Letter

Day One Announces Oversubscribed $175.0 Million Private Placement - GlobeNewswire

Cancer Biotech Day One Biopharma Expands to ADCs, Paying $55M to Nab a Phase 1-Ready Drug - MedCity News

Solving for the medical and business case in pediatric cancer — Day One - BioCentury

Join us at the Patient Recruitment for Rare Disease Trials Summit, December 10-12 in Boston! Our very own Kelli Wright, Director of Patient Advocacy, will be sharing examples on how to include patient input into clinical trial design at any stage of your program.

Learn more about the conference here: https://ter.li/7b1o12

 Where Day One Biopharmaceutical Stands With Analysts 

Rx Rundown: Merck, Marea, Day One Biopharmaceuticals and more - MM+M Online

 Day One Biopharma in-licenses VRK1 from Sprint Bioscience 

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development - GlobeNewswire


                                            Tovorafenib details                                        

The Day One team is excited to be at the 29th Annual Meeting of the Society for Neuro-Oncology in Houston this week! Stop by our booth (423) to hear how we're redefining what's possible for people of all ages living with cancer.

Investigators from the phase 2 FIREFLY-1 trial will be presenting data on Friday, November 22. See poster presentation details below. Learn more: https://bit.ly/4eqA1vg

 Day One inks $1.2B biobucks pact for MabCare’s solid tumor ADC 

 Day One Biopharmaceuticals management to meet with Piper Sandler 

Day One Expands Pipeline with Potential First-in-Class - GlobeNewswire

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor - GlobeNewswire

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - GlobeNewswire

Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts? - Yahoo Finance

 Pediatric Brain Tumor Foundation celebrates FDA approval of Day One Biopharmaceuticals' OJEMDA™, new ... 

 Vice President, Product Team Leader job with Day One Biopharmaceuticals | 2888322 

FDA gives accelerated approval to Day One’s targeted treatment for most common brain tumor in kids - Endpoints News


                                            Learn about OJEMDA™                                        

Day One inks $1.2B biobucks pact for MabCare’s solid tumor ADC - Fierce Biotech

Compliance

Charles Schwab Investment Management Inc. Acquires 64,700 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat

Publications & posters

 Raf kinase inhibitors for treating tumors harboring gene fusions 

Day One jets off with Sprint's VRK1 program for up to $316M

With $111M upfront investment, Ipsen secures ex-US rights to Day One's pediatric cancer med - FiercePharma

Day One Biopharmaceuticals

Business:

Drug notes:

About: